Last Updated: September 29, 2026

Litigation Details for ACQIS LLC v. Hon Hai Precision Industry Co., Ltd. (W.D. Tex. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in ACQIS LLC v. Hon Hai Precision Industry Co., Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .
Biologic Drugs cited in ACQIS LLC v. Hon Hai Precision Industry Co., Ltd.
The biologic drug covered by the patents cited in this case is ⤷  Start Trial .

Litigation summary and analysis for: ACQIS LLC v. Hon Hai Precision Industry Co., Ltd. (W.D. Tex. 2023)

Last updated: July 20, 2026

ACQIS LLC v. Hon Hai Precision Industry Co., Ltd. (6:23-cv-00264): Litigation Summary, Patent Claims, and Procedural Posture

ACQIS LLC’s infringement suit against Hon Hai Precision Industry Co., Ltd. in case 6:23-cv-00264 (E.D. Texas) is a patent enforcement action filed in 2023. The docket establishes a standard U.S. patent litigation pathway: initial complaint and service, responsive pleadings, Markman scheduling, discovery, and dispositive motion practice. The case posture and claim scope turn on the specific asserted patents, parties, and claim constructions that appear in the operative pleadings and the court’s scheduling and claim construction orders.

What does the docket show in ACQIS LLC v. Hon Hai Precision Industry Co., Ltd., 6:23-cv-00264?

Core case identifiers

  • Case name: ACQIS LLC v. Hon Hai Precision Industry Co., Ltd.
  • Court: U.S. District Court (Eastern District of Texas)
  • Case number: 6:23-cv-00264
  • Filed: 2023 (based on docket year; specific filing date appears on the complaint and docket entry)

What to extract from the docket for infringement risk

  • Asserted patent set: the complaint lists the U.S. patents asserted and the specific claims alleged to be infringed.
  • Accused products / technology: the complaint ties infringement to specific Hon Hai products, models, or features (often framed as devices and components).
  • Relief sought: typical relief includes damages, injunctive relief (rarely granted in practice), and attorneys’ fees and costs if statutory bases apply.
  • Procedural posture: status is determined by (a) whether a scheduling order has issued, (b) whether claim construction has occurred, (c) whether parties have reached an agreement or stipulated dismissal, and (d) whether dispositive motions are resolved.

Litigation analysis frame In E.D. Texas patent cases, the litigation value drivers are:

  1. Claim construction outcomes for the asserted independent claims.
  2. Technical claim mapping sufficiency (whether plaintiff’s infringement contentions and charts survive scrutiny).
  3. Validity defenses (anticipation/obviousness theories and how they track the court’s claim constructions).
  4. Infringement posture for Hon Hai: product identification, use-based theories, and whether the accused systems include the claimed elements.

What patents are asserted in ACQIS LLC v. Hon Hai Precision Industry Co., Ltd., 6:23-cv-00264?

A complete litigation summary that identifies which patents are asserted and which claims are alleged requires the complaint’s list of asserted U.S. patents and the operative infringement contentions.

No asserted-patent numbers or claim lists are included in the information provided here, so a claim-by-claim analysis is not possible.

What is the procedural timeline for 6:23-cv-00264 (filing, scheduling, Markman, discovery, motions)?

A complete procedural timeline also requires the docket’s dated entries (e.g., complaint filing date, service confirmation, Rule 16 scheduling order date, Markman hearing date, and order dates).

With no docket entry timestamps provided, only the generic U.S. patent litigation structure can be stated: complaint and service, responsive pleading, scheduling order, Markman, infringement and invalidity contentions, fact discovery, expert discovery, claim construction-related briefing, dispositive motions, and pretrial orders.

How strong are ACQIS LLC’s infringement theories against Hon Hai in 6:23-cv-00264?

An infringement strength assessment depends on:

  • How the accused Hon Hai products are defined
  • Whether the plaintiff’s theories are device-based (system components) or method-of-use
  • Whether infringement hinges on installed base use, specifications, or internal component design

No infringement theory details, product descriptions, or claim mapping excerpts are included in the information provided, so strength cannot be quantified.

What validity challenges are raised in ACQIS LLC v. Hon Hai Precision Industry, 6:23-cv-00264?

Validity analysis requires:

  • The anticipated prior art and obviousness combinations asserted
  • Whether defenses target system claims or component sub-features
  • Whether Hon Hai challenges written description/enablement, indefiniteness, or priority

No invalidity content is provided here, so it cannot be analyzed.

What does the case posture imply for settlement versus trial in 6:23-cv-00264?

Settlement likelihood in patent cases generally correlates with:

  • Stage of claim construction
  • Expert report exchange completion
  • Whether key invalidity/indefiniteness issues are already briefed
  • Whether there are multiple asserted patents with staggered lifetimes

This case posture cannot be assessed without dated docket events (e.g., whether claim construction orders are entered, whether trial is scheduled, whether a stipulation or dismissal appears).

Is there any Paragraph IV or Orange Book generics risk in ACQIS LLC v. Hon Hai (6:23-cv-00264)?

Paragraph IV and Orange Book issues are specific to ANDA filings for small-molecule generics. This case is not described as a Hatch-Waxman FDA/Orange Book matter; the defendant is a hardware manufacturer (Hon Hai). Without information indicating an FDA-regulated drug product, there is no basis to identify Paragraph IV exposure.

How does Hon Hai typically respond in patent cases, and what does that mean for this matter?

Without docket-specific filings, any response characterization would be generic. Typical defenses include non-infringement, invalidity, indefiniteness, and lack of standing or improper venue arguments where applicable. A matter-specific analysis requires the answers, motions, and claim construction briefing.

What are the business implications of ACQIS LLC v. Hon Hai for product lines and IP licensing?

Even without patent numbers, the business implications in a standard platform-like hardware defendant case include:

  • Potential licensing leverage tied to claim breadth and coverage of common components.
  • Production and supply chain impacts if injunctive relief becomes a credible risk.
  • Prior art search and engineering review costs for accused feature sets.

A quantifiable risk assessment requires asserted patent claim scope and accused product mappings.

What Key Takeaways matter for stakeholders monitoring ACQIS LLC v. Hon Hai (6:23-cv-00264)?

  • Case is a 2023 E.D. Texas patent infringement action by ACQIS LLC against Hon Hai Precision Industry Co., Ltd. under 6:23-cv-00264.
  • Meaningful litigation risk depends on asserted patent identities and operative claim constructions, which are not specified in the provided inputs.
  • Settlement/trial forecasting is not possible without docket milestones such as scheduling, Markman orders, expert disclosures, and dispositive motion outcomes.
  • No basis exists to evaluate Paragraph IV/Orange Book exposure from the case description alone.

FAQs

  1. What does “6:23-cv-00264” identify in patent litigation?
    It is the federal docket number and case identifier used to track filings, orders, and procedural milestones in the U.S. district court.

  2. Does an E.D. Texas patent case usually proceed to Markman claim construction?
    Yes, most patent cases in E.D. Texas follow a schedule that includes claim construction briefing and a Markman hearing unless the parties resolve or narrow the case.

  3. How do claim construction rulings typically impact infringement outcomes?
    Claim construction can narrow key terms, which often determines whether the accused products map onto the construed elements.

  4. What evidence matters most for infringement contentions in hardware patent suits?
    Product specifications, component-level design details, technical drawings, sales/usage scenarios, and documented feature correspondence.

  5. Can this case affect licensing strategy for Hon Hai or other electronics suppliers?
    Yes, if the asserted claims cover broadly deployed components or design patterns, it can drive cross-licensing discussions or require portfolio-wide defenses.

References

  1. ACQIS LLC v. Hon Hai Precision Industry Co., Ltd., 6:23-cv-00264, U.S. District Court (Eastern District of Texas) (docket-based information referenced).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.